Plus, how to ignore online noise, OpenAI’s big pay packages and what’s ahead in the chip wars, in this edition of the Technology newsletter.https://www.wsj.com/tech/testing-ai-fitness-coaches-34e42b98?mod=rss_Technology
New virtual trainers from Fitbit, Peloton and Apple aim to keep your workouts on track.https://www.wsj.com/tech/personal-tech/ai-fitness-coach-1ca345ec?mod=rss_Technology
Elon Musk could become the world’s first trillionaire, even without his new Tesla pay package.https://www.wsj.com/tech/elon-musk-net-worth-trillionaire-2026-c4300aa3?mod=rss_Technology
Xiaomi’s electric-vehicle plant is more difficult to get into than some competitive colleges. Parents and influencers vie for an edge.https://www.wsj.com/lifestyle/travel/the-hardest-reservation-in-china-is-a-factory-tour-3df0d4cc?mod=rss_Technology
June Paik spurned a takeover offer from Meta Platforms last year. Now his company, Furiosa, has an AI chip entering mass production.https://www.wsj.com/tech/ai/furiosa-chip-nvidia-challenge-june-paik-5d3dc304?mod=rss_Technology
Find insight on Telus, European AI-related stocks and more in the latest Market Talks covering Technology, Media and Telecom.https://www.wsj.com/articles/tech-media-telecom-roundup-22431c67?mod=rss_Technology
ChatGPT apps are a key piece of OpenAI’s long-shot bid to replace Apple. Many aren’t yet useful.https://www.wsj.com/tech/ai/openai-apple-app-store-sam-altman-7a9b08ca?mod=rss_Technology
Plus, WSJ’s 2026 tech predictions, sleep-enhancing beverages and chatbot psychosis.https://www.wsj.com/tech/ai/ticketed-by-a-police-drone-a9ee1b91?mod=rss_Technology
In an age of endless low-quality information, it’s time to fight our instinct to seek out and absorb all we can. It takes practice.https://www.wsj.com/tech/personal-tech/critical-ignoring-social-media-7e236f52?mod=rss_Technology
Investors shared their market predictions with WSJ Pro VC, voicing optimism and concern.https://www.wsj.com/articles/venture-capitalists-predict-many-ai-startups-will-get-weeded-out-in-2026-61134d89?mod=rss_Technology
More people are resolving to spend less time on their phones and social media, and research suggests there are health benefits.https://www.wsj.com/health/wellness/what-a-digital-detox-can-do-for-you-e4b0b893?mod=rss_Technology
The company looked to be in an unfixable decline when he took over in 1993—and changed its focus from hardware to services.https://www.wsj.com/tech/personal-tech/louis-gerstner-ibm-ceo-dies-b8be8b1b?mod=rss_Technology
Audiobooks remain a bright spot in publishing though the pace of growth has slowed.https://www.wsj.com/tech/personal-tech/listen-to-this-some-audiobooks-are-outselling-hardcovers-179ed593?mod=rss_Technology
Plus, teen AI founders, humanoid-robot hype, Nvidia’s fresh Groq deal, China’s AI fears and more, in this edition of the Technology newsletter.https://www.wsj.com/tech/ai/our-tech-columnists-annual-predictions-folding-iphones-mind-reading-tech-ev-supercars-d4e6541b?mod=rss_Technology
With just a few gear upgrades and some canny strategies, you can make your experience not just tolerable, but maybe even a little luxurioushttps://www.wsj.com/lifestyle/travel/how-to-make-your-economy-class-plane-seat-better-9cc7905f?mod=rss_Technology
A life-sciences job in Boston used to be a sure path to a high-paying career, but empty labs and unemployed grads now herald tougher times in the city.https://www.wsj.com/tech/biotech/ph-d-s-cant-find-work-as-bostons-biotech-engine-sputters-729f0036?mod=rss_Technology
Lifordi Immunotherapeutics and other biotechnology companies are using antibodies to precisely target drugs in the body.https://www.wsj.com/articles/startup-lifordi-seeks-to-deliver-potent-medication-for-autoimmune-diseases-11e134f9?mod=rss_Technology
The French drugmaker is looking to dealmaking after some experimental drugs missed their goals in clinical studies or were turned down by regulators.https://www.wsj.com/business/deals/sanofi-to-buy-vaccine-maker-dynavax-in-2-2-billion-deal-8d99d55b?mod=rss_Technology
BioMarin Pharmaceutical has struck a deal to buy fellow biotechnology company Amicus Therapeutics for about $4.8 billion in cash.https://www.wsj.com/business/deals/biomarin-to-buy-amicus-therapeutics-for-4-8-billion-c338bf7d?mod=rss_Technology
A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of the disease didn’t hit its main goal.https://www.wsj.com/health/pharma/sanofi-multiple-sclerosis-drug-hit-by-double-setback-2760a61c?mod=rss_Technology